Information Provided By:
Fly News Breaks for July 22, 2019
GLMD
Jul 22, 2019 | 07:50 EDT
Laidlaw analyst Francois Brisebois initiated Galmed with a Buy rating and $25 price target, citing his belief that the company's Aramchol could be a "great candidate" for a combination treatment for Nonalcoholic Steatohepatitis, or NASH. Galmed expects to initiate a Phase 3/4 trial of Aramchol in Q3 and report data from its first part by the end of 2022, Brisebois noted.
News For GLMD From the Last 2 Days
There are no results for your query GLMD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.